Prostate Biopsy

The scan decides whether you need the needle. The route decides whether it makes you ill.

Two decisions sit in front of every man sent for a prostate biopsy, and neither one is about the needle itself, since an MRI taken beforehand cancels the biopsy outright in roughly a quarter of men and aims it in all the rest. The route the needle takes, through the rectum or through the skin behind the scrotum, changes how much cancer gets found and how likely you are to end up in hospital with a fever.

What the procedure actually involves

A spring loaded needle fires through the prostate and back out in a fraction of a second, taking with it a thread of tissue roughly one millimeter across and fifteen to twenty millimeters long. Each thread counts as one core. Somewhere between ten and twenty four of them come out in a single sitting, depending on the scheme, and each one gets labelled with the exact part of the gland it came from before it goes into a pot of formalin. An ultrasound probe in the rectum supplies the picture during both routes, since the prostate sits directly against the rectal wall and no other window gives that view, and local anesthetic goes in first, into the nerve bundles beside the gland or into the skin and the deeper tissues, depending on which route is being used. The whole thing takes ten to twenty minutes and you go home the same day. What decides the outcome is not the needle, which has changed very little in thirty years. It is where the needle is aimed and where it enters.

Everything else on this page follows from those two choices.

Two decisions, and neither one is the needle

The first decision cancels the procedure for some men

A raised PSA used to lead straight to twelve cores through the rectal wall, because nobody had a way of looking inside the gland first, and multiparametric MRI changed that in a way larger than most men are ever told. The scan finds the tumors that matter, misses very few of them, and produces a clear result often enough that a substantial share of men walk out with no biopsy at all. That is the first decision, and a urologist who books your biopsy before reading a scan has skipped it.

What the scan can and cannot do

Somebody tested this properly, which in diagnostic research means comparing both tests against a third test good enough to serve as the truth, so 740 men were enrolled and 576 completed the full sequence, having an MRI, then the standard ultrasound guided biopsy, then a mapping biopsy that samples the whole gland on a five millimeter grid under anesthesia. Each test was read without knowledge of the others. Against that reference, 71 percent of the men had cancer of some kind and 40 percent had cancer that mattered. The MRI picked up 93 percent of the serious cancers. The old ultrasound guided biopsy picked up 48 percent of them. The same study also recorded, carefully, what the whole exercise cost the men who took part in it. 44 of the 740 enrolled reported a serious adverse event and eight of them developed sepsis, which is the kind of figure that explains why so much effort has gone since into biopsying fewer men and into reaching the prostate without crossing the bowel at all.

The report you receive will carry a PI-RADS score, and the score decides what happens next.

1. PI-RADS 1 and 2 mean the radiologist sees nothing suspicious. Most of these men need no biopsy, and the decision turns on PSA density and on what your PSA has done over time.
2. PI-RADS 3 is the honest shrug. Roughly one in five of these harbors serious cancer, PSA density usually settles it, and this is the score where a second radiologist earns his fee.
3. PI-RADS 4 means a lesion likely to be cancer. Biopsy, with cores aimed at the lesion.
4. PI-RADS 5 means a lesion very likely to be cancer and large enough to be obvious. Biopsy, and the result rarely surprises anyone.

Scanner quality and radiologist experience change these numbers more than any of the trials can show, so a scan done on a 1.5 Tesla machine by somebody who reads four prostate studies a month is a different test from the one the trials used.

When a clear scan is enough

Swedish investigators ran the biggest test of this question inside a screening program. 37,887 men aged fifty to sixty were invited and 17,980 took part. Anybody with a PSA of three or above went for an MRI. A third of them were then randomly assigned to have systematic cores as well as targeted ones, and the remainder had targeted cores only, with no biopsy at all when the scan was clear. Harmless cancer was diagnosed in 0.6 percent of the targeted only group against 1.2 percent of the group that also had systematic cores, less than half as much overdiagnosis, and serious cancer came out statistically similar between the two, with a relative risk of 0.81 and a confidence interval stretching from 0.60 to 1.1.

Ten men paid for that. Their serious cancer showed up only in the systematic cores, so a targeted only policy would have missed it for the time being. All ten had intermediate risk disease, nearly all of it small in volume, and every one of them went onto active surveillance rather than straight to treatment, which is the mildest form of a missed diagnosis anybody could hope for.

PSA density decides most of the remaining arguments. Divide your PSA by the volume of your prostate in milliliters, both of which appear on reports you already have. Anything under 0.10 alongside a clear scan makes cancer unlikely enough that watching is reasonable, and readings above 0.15 alongside a clear scan keep the conversation open, since a large PSA coming from a small gland has to be coming from somewhere. Any urologist recommending for or against a biopsy without mentioning that calculation is working with less information than he already has. Two cautions travel with the number. Prostate volume measured on ultrasound and prostate volume measured on MRI frequently differ by a fifth or more, so the density you calculate depends on which report you used, and a threshold applied to the wrong volume is a threshold applied to nothing. A PSA drawn within days of a urine infection, a long bicycle ride or ejaculation reads higher than the man's true baseline, and that is the reason we ask for the whole run of readings instead of the single one that triggered the referral.

Targeted cores, systematic cores, or both

Two good trials, two different answers

French investigators at sixteen centers gave 251 men both kinds of biopsy in the same sitting, with one operator taking twelve systematic cores while masked to the scan and a second operator taking cores aimed at whatever the MRI had flagged. Serious cancer turned up in 94 of the men. Systematic cores alone found 29.9 percent of the group, targeted cores alone found 32.3 percent, and the difference between those two was not significant. The interesting part sits underneath. 13 of the 94 cancers were found by systematic cores only, 19 by targeted cores only, and 62 by both. Dropping the systematic cores would have missed serious cancer in 5.2 percent of the men, and dropping the targeted cores would have missed it in 7.6 percent.

Set that beside the randomized trial quoted higher up and the two results disagree in a way that is easy to state and hard to resolve, since one found targeted cores alone superior to systematic cores alone. The other found each kind catching cancers the other missed. Both are correct, and the explanation is that they measured different things, since a trial randomizing whole strategies answers the question of policy while a paired study giving every man both tests answers the question of anatomy.

1. A clear scan with a low PSA density usually means no biopsy at all, and the men in that group are the largest single beneficiaries of the whole change.
2. A clear scan with a high PSA density argues for systematic cores, since the cancer the scan cannot see is precisely the one the untargeted needle might still hit.
3. A lesion on the scan gets targeted cores without question, and the argument concerns how many extra systematic cores go alongside.
4. A man who is likely to end up on active surveillance benefits from the fuller picture, because surveillance is only as good as the map it started from.

Where the needle goes in

The rectal route has been standard for forty years and its problem becomes obvious once somebody says it out loud, because the needle passes through the wall of the bowel, carrying whatever lives there into the prostate and the bloodstream, twelve or more times in a row. The perineal route puts the needle through cleaned skin behind the scrotum instead and never touches the bowel, and it reaches the front of the gland more easily, which is where the rectal route has always struggled. Until recently the argument against it was that it needed a general anesthetic. Local anesthetic techniques ended that argument some years ago, and a large randomized trial has since tested everything that remained in dispute. The front of the gland deserves a sentence of its own here. Tumors sitting in the anterior part of the prostate are the ones a rectal needle reaches worst, since it has to cross the whole depth of the gland to get there, and they are a recognized cause of a clean biopsy in a man whose PSA carries on climbing.

1,126 men at ten hospitals were randomly assigned to one route or the other. All of them had an MRI beforehand and none had been biopsied before.

Serious cancer was found in 60 percent of the perineal group against 54 percent of the rectal group, an odds ratio of 1.32 with a confidence interval from 1.03 to 1.70, and infection needing a hospital admission within five weeks happened to 2 men out of 562 in the perineal group against 9 men out of 564 in the rectal group. Serious adverse events overall ran at 2 percent against 4 percent. Urinary retention needing a catheter, urinary symptom scores at four months and sexual function scores at four months came out the same in both groups, and overall complication reporting was statistically indistinguishable at 81 percent against 77 percent, which tells you that minor complaints are near universal after either route. Read that last pair of figures carefully. Eight men in ten reported something they counted as a complication, and in a trial that asks systematically, most of that means blood, ache and discomfort rather than anything dangerous.

One finding went the other way, and it is the one men ask about most.

The perineal route hurt more at the time and embarrassed men more, reported by 38 percent against 27 percent, an odds ratio of 1.84, and that is a real cost lasting for the length of the appointment, which is the sort of trade most men accept once somebody has stated both halves of it plainly. More cancer found, fewer hospital admissions for infection, and a more uncomfortable twenty minutes.

The antibiotic that stopped working

Ciprofloxacin went in before nearly every transrectal biopsy for two decades, on the reasonable grounds that it covered the organisms living in the bowel, and those organisms declined to stay covered. A randomized study of 157 men swabbed the rectum ten days before biopsy and cultured what grew, and 56.3 percent of the men were carrying fluoroquinolone resistant Enterobacterales, all of them E. coli. Recent use of a fluoroquinolone within the previous six months predicted carriage. For men in that position, the prophylaxis was switched to a third generation cephalosporin on the strength of the swab, and infectious complications after the biopsy fell. Resistance is local, which is the practical point for anybody traveling for treatment. The organisms living in a man's bowel reflect where he has lived and what he has been prescribed, so a prophylaxis policy written for one country can be the wrong policy for a patient arriving from another, and a rectal swab costs almost nothing set against a week of intravenous antibiotics on a ward.

Shaking chills and a temperature above 38 degrees in the two days after a rectal biopsy mean going to a hospital the same evening. Waiting until morning is how a treatable infection turns into a week on a ward.

What the appointment feels like

You arrive having eaten normally, having stopped blood thinners if you were told to and having taken any antibiotic you were given. An enema goes in beforehand for the rectal route. You lie on your side with your knees drawn up for that route, or on your back with your legs supported for the perineal one. The ultrasound probe goes in, the gland gets measured, and the local anesthetic follows. Waiting a few minutes after the anesthetic makes a large difference and some operators skip it. That pause matters more than the drug does. Request those few minutes and use them, since a block that has taken properly turns the procedure from genuinely unpleasant into merely undignified.

Each core makes a loud click and a brief thump. Most men describe pressure rather than sharp pain, some find it genuinely uncomfortable, and nobody enjoys it. Talk to the person doing it while it happens, since operators adjust when they know where you are up to. You then rest for twenty minutes and pass urine before leaving, which proves nothing has blocked, and then you go home.

Bring somebody with you and do not plan anything for the rest of the day.

The days afterward

Blood appears in three places and each one runs on its own timetable, which nobody explains often enough and which accounts for a large share of the worried messages we receive. Blood in the urine settles within a few days. Blood in the semen persists for four to six weeks and occasionally longer, turning it rust colored or dark brown, and it alarms men who were told nothing about it, while blood from the back passage happens only after the rectal route and stops within a day or two. Drink more than usual, avoid heavy lifting and hard exercise for a couple of days, and expect to feel a dull ache low down that settles with ordinary painkillers.

Three things behave differently and each needs same day attention. Being unable to pass urine at all. A fever with shaking. Bleeding heavy enough to fill a toilet bowl or to keep going past two days. None of those is common and all of them are manageable when they are dealt with quickly, which is the whole reason we insist that men having a biopsy far from home stay within reach of the hospital for the first forty eight hours. Retention is the likeliest of the three and the easiest to settle. Swelling from the cores and the anesthetic narrows a channel that was already narrow, a catheter goes in for a day or two, and the problem clears as the swelling does. Men with a large gland and a poor stream beforehand are the ones it happens to.

Resume sex whenever it feels comfortable. Use contraception until the blood clears if pregnancy would be unwelcome.

Reading the pathology report

Reports arrive after seven to ten working days and they differ enormously in how much they tell you. A good one names every core, says which ones held cancer and how much of it, and grades the whole set. A poor one gives a single Gleason score and a sentence. That gap matters because the three conversations you have next, on surveillance, on surgery and on radiotherapy, all depend on knowing where inside the gland the disease sits and how much of it there is, so send us whatever you were given and we will say plainly whether it is enough to plan with.

The four items a report has to contain

How many cores were taken and how many of them held cancer. The grade group, from one to five, describing how disordered the cells look and carrying more weight than any other line on the page. The maximum length of cancer in any single core, in millimeters, which separates a speck from a mass. And the names of the involved cores, which is what tells a surgeon which side to spare and a radiotherapist where to aim. A report giving only a Gleason score with no core map is incomplete, and the laboratory that produced it can supply the full version on request.

If the report says no cancer

Relief is reasonable and closure is not. A negative biopsy after a clear MRI reassures properly, and a negative biopsy after a suspicious MRI raises the question of whether the needle reached the lesion at all, so have the two documents read side by side, since a PI-RADS 4 lesion with no cancer underneath it deserves either a repeat targeted biopsy or a written explanation of why none is needed. Your PSA gets repeated in six to twelve months either way, and a rising trend across several tests carries far more weight than any single reading.

If the report says cancer

Grade group one in one or two cores, with a low PSA density, usually leads to surveillance rather than treatment, and men are frequently surprised to hear that doing nothing is the recommended option. A report showing grade group two opens a real decision between surgery, radiotherapy and continued surveillance, with the balance turning on your age, your other health and the volume of disease, while grade group three and above moves the conversation toward treatment and toward scans that check whether anything has spread. Nothing has to be decided in the first week. Every option on that list will still be available in a month, and a second opinion on the pathology slides costs very little and changes the grade more often than most men expect. A second habit belongs in that first week. Take the report to somebody with no financial interest in what you decide next, because the same grade group reads differently in a surgical clinic and in a radiotherapy clinic, and whichever version you hear first tends to stick.

Cost, travel and flying home

Biopsy runs as a day procedure and the travel around it stays short, which makes this one of the easier reasons to come here. Four to six nights covers everything comfortably. The table below sets out how those nights get used.

This table scrolls sideways on a narrow screen. Drag or swipe to see every column.

Fitness to fly

Flying two days after a biopsy is medically straightforward, and the reason we ask for forty eight hours has nothing to do with the cabin and everything to do with where you are when a fever starts. Infection after a rectal biopsy declares itself in the first two days almost without exception, and a man in a hotel ten minutes away gets treated within the hour while a man over the Atlantic does not. Bleeding follows the same logic. Book a return flight you can move, keep our number on your phone, and carry the antibiotic we send you home with.

What to send before you come

Every PSA result you have ever had with the date attached to each one, your prostate volume from any scan or ultrasound, the MRI report together with the images themselves on a disc or a link, a list of your medications with particular attention to blood thinners, a note of every antibiotic taken in the last six months, and any previous biopsy report. One of our urologists reads all of it and replies in writing at no charge, and a fair number of those replies say that your scan and your PSA density argue against a biopsy for now. Cost here moves with three things, namely whether the MRI is done at home or here, which route is used and how many cores are planned, and whether the pathology sits inside the quoted figure. Get those three in writing before you book anything. Nothing on that list is unusual, and every document named already exists somewhere in your own records.

One coordinator handles the whole visit and stays reachable on WhatsApp once you are home, which matters more for a biopsy than for an operation, since the result arrives after you have left. English, Arabic, French, Russian, Serbian, Romanian and Spanish are spoken in the building and anything else gets interpreted on request. A companion can come to every appointment. Hotel and airport transfers are arranged around your dates, halal, vegetarian and diabetic meals are ordinary here, a prayer room sits on the ground floor, and visa invitation letters go out roughly ten days ahead. When the report comes through, a urologist here will go through it with you on a call at no charge, whatever it says.

We publish no prices. A figure quoted before anyone has read your PSA history is a number chosen to win an inquiry.

Prostate biopsy FAQ

Seven questions arrive more often than the rest.

References

1. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine. 2018;378(19):1767-1777.
2. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS), a paired validating confirmatory study. Lancet. 2017;389(10071):815-822.
3. Bryant RJ, Marian IR, Williams R, Lopez JF, Mercader C, Raslan M, et al. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE), a multicentre, randomised, controlled trial. Lancet Oncology. 2025;26(5):583-595.
4. Hugosson J, Mansson M, Wallstrom J, Axcrona U, Carlsson SV, Egevad L, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. New England Journal of Medicine. 2022;387(23):2126-2137.
5. Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST), a prospective, multicentre, paired diagnostic study. Lancet Oncology. 2019;20(1):100-109.
6. Bouzouita A, Rehaiem A, Saadi A, Zaghbib S, Chakroun M, Ayed H, et al. Antimicrobial prophylaxis protocol based on rectal swab culture before prostate biopsy to prevent infectious complications, a prospective randomized comparative study. International Urology and Nephrology. 2024;56(8):2495-2502.